
(CBRS)
Cerebras Systems (Derivatives) (CBRS) price prediction for 2026-2030Not listed
How has Cerebras Systems (Derivatives) (CBRS) performed this year? What are the short-term outlooks (1 week, 1 month, 3 months) and the long-term forecast for 2026-2030? We analyze and forecast CBRS's future price based on recent trends, historical data, and technical indicators such as Moving Averages (MA), RSI, and MACD. You can also use our price prediction tool to estimate potential returns by setting your target growth rate.
Cerebras Systems (Derivatives) (CBRS) price
Last updated: Aug 19, 2026, 23:08:45
24h high
259.15 USD
Market cap
- USD
24h low
223.30 USD
24h volume
- USD
Cerebras Systems (Derivatives) (CBRS) price
217.44 USD
Date
--
Enter your expected growth for Cerebras Systems (Derivatives) to calculate its future value
Current price
217.44 USD
Momentum
Bearish
14D RSI
44.21
50D SMA
205.36 USD
200W SMA
224.5 USD
Fear & Greed
55
1. Weekly EMA 200
The weekly EMA 200 is a widely used bull/bear market divider and long-term trend line in crypto.
2. Daily EMA 50
3. MACD trend & reversal signals
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.